Respiratory Syncytial Virus (RSV) Infections drugs in development, 2023

Crossover rounds ap­pear to be trick­ling back in­to biotech. Dur­ing the boom times of 2020 and 2021, there was a flood of mon­ey from pub­lic-mar­ket

When Re­gen­eron an­nounced a $500 mil­lion cor­po­rate ven­ture cap­i­tal fund last week, it was the first time in years that a sto­ried large phar­ma had

GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical, with 21